WATSON LABS TEVA
GenericsWATSON LABS TEVA is a generic drug manufacturer focused on Cardiovascular, Immunology, Neurology.
WATSON LABS TEVA at a Glance
- Strong track record with 83% execution quality across 12 trials
- Fast trial execution (9 months median completion)
WATSON LABS TEVA's Key Drugs
WATSON LABS TEVA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
WATSON LABS TEVA's Recent FDA Approvals
New NDA/BLA approvals for WATSON LABS TEVA over the last two years — novel drugs only, excluding generics and label supplements.
WATSON LABS TEVA's Therapeutic Areas
WATSON LABS TEVA's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WATSON LABS TEVA's Top Competitors
WATSON LABS TEVA's closest competitors by therapeutic-area and drug-target overlap include Takeda, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WATSON LABS TEVA Pipeline Snapshot
Active clinical trials for WATSON LABS TEVA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/2 completed
- • Speed: 9 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 1974-01-29
- Latest
- 2026-06-18
- Applications
- 51
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges